
    
      This is a phase Ⅰ clinical trial of recombinant hepatitis B vaccine (Hansenula
      polymorpha,10μg) with an open-labelled design in adults and randomized, double-blinded, and
      positive controlled design in children and neonates. The control vaccine was the
      commercialized recombinant hepatitis B vaccine (Hansenula polymorpha,10μg) manufactured by
      Dalian Hissen Bio-pharm Lnc. Twenty four adults aged from 18 to 49 years will be vaccinated
      with one dose of investigational vaccine. Sixty children aged from 1 to 15 years will be
      randomly assigned in a 1:1 ratio to receive one dose of in investigational vaccine or control
      vaccine. Sixty neonates will be randomly assigned in a 1:1 ratio to receive three doses of
      investigational vaccine or control vaccine on the schedule of month 0,1,2. Safety profiles 30
      days after each dose will be assessed based on all the participants, and immunogenicity will
      be assessed based on the enrolled chidren and neonates.
    
  